Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB00188_nanopub.RA3SE6FCVcinGNcqGFlICll3zha-1j7i7wAb3lt7zqn4U#assertion>. }
Showing items 1 to 22 of
22
with 100 items per page.
- drugbank:DB00188 type drugbank_vocabulary:Drug assertion.
- drugbank:DB00188 label "Bortezomib [drugbank:DB00188]" assertion.
- drugbank:DB00188 seeAlso velcade.htm assertion.
- drugbank:DB00188 seeAlso bortezomib.html assertion.
- drugbank:DB00188 seeAlso DB00188 assertion.
- drugbank:DB00188 description "Bortezomib (originally PS-341 and marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease." assertion.
- drugbank:DB00188 identifier "drugbank:DB00188" assertion.
- drugbank:DB00188 title "Bortezomib" assertion.
- drugbank:DB00188 drugbank_vocabulary:x-cas cas:179324-69-7 assertion.
- drugbank:DB00188 drugbank_vocabulary:drugbank-id "APRD00828" assertion.
- drugbank:DB00188 drugbank_vocabulary:drugbank-id "DB00188" assertion.
- drugbank:DB00188 bio2rdf_vocabulary:x-identifiers.org DB00188 assertion.
- drugbank:DB00188 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB00188" assertion.
- drugbank:DB00188 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB00188 bio2rdf_vocabulary:identifier "DB00188" assertion.
- drugbank:DB00188 drugbank_vocabulary:x-wikipedia wikipedia:Bortezomib assertion.
- drugbank:DB00188 drugbank_vocabulary:x-pharmgkb pharmgkb:PA10252 assertion.
- drugbank:DB00188 drugbank_vocabulary:x-dpd dpd:2262452 assertion.
- drugbank:DB00188 drugbank_vocabulary:x-chebi chebi:52717 assertion.
- drugbank:DB00188 drugbank_vocabulary:x-atc atc:L01XX32 assertion.
- drugbank:DB00188 drugbank_vocabulary:x-ahfs ahfs:10:00.00 assertion.
- drugbank:DB00188 drugbank_vocabulary:x-ndc ndc:63020-049-01 assertion.